Richard G. Lalonde, MD
Primary Axis:
Infection and Immunity
Email:
Email contact form Research Focus:
HIV and Hepatitis C; clinical trialsHuman immunodeficiency virus, AIDS, hepatitis C
Keywords:
Human immunodeficiency virus, AIDS, hepatitis C
Location:
Montreal Chest Institute Publications:
Keller, Marina, Lu,Ying, Lalonde, Richard G, Klein, Marina B. Impact of HIV-I viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS.2009; 23(6): 731-737.
Gathe JC, Pierone G, Piliero P, Arasteh K, Rubio R, Lalonde RG, Cooper D, Lazzarin A, Kohlbrenner VM, Dohnanyi C, Sabo J, Mayers D. Efficacy and Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-lnfected Patients. AIDS Res Hum Retroviruses. 2007;23:216-23.
AI-Morhi H, Murphy T, Lu Y, Lalonde R, Klein MB. Evaluating liver fibrosis and the impact of antiretroviral therapy in HIV and Hepatitis C Co-infection Using a Non-invasive Marker. J Acquir Immune Def Syndr. 2007; 44:463-9.
